Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 14, 2025, titled "Press Release and Management Discussion & Analysis".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals reported Q1 FY26 consolidated revenue of Rs. 32,644 Mn, up 0.6% year-on-year. India business grew 3.7% YoY to Rs. 12,399 Mn, while North America rose 8.9% quarter-on-quarter to Rs. 7,780 Mn on the back of injectable and partnered product launches. Europe revenue declined 4% YoY to Rs. 6,678 Mn, and Emerging Markets were nearly flat at Rs. 5,721 Mn. EBITDA stood at Rs. 5,805 Mn with a 17.8% margin, and adjusted profit after tax was Rs. 3,129 Mn (9.6% margin), adjusted for a US litigation settlement charge. The company highlighted its US subsidiary's USD 37.75 Mn settlement of antitrust class-action lawsuits. On the innovation side, IGI (Ichnos Glenmark Innovation) signed a landmark global licensing deal with AbbVie for its oncology drug ISB 2001, entitling it to a USD 700 million upfront, up to USD 1.225 billion in milestones, and tiered double-digit royalties.
The quarter showed flat top-line growth with mixed regional performance, but the adjusted PAT margin of 9.6% indicates decent profitability. The AbbVie deal is a significant positive for long-term value, providing a large non-dilutive cash inflow and validating the innovation pipeline, while the US legal settlement removes a key overhang pending court approval.